Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results from human cell line tests have shown that Senesco's factor eIF-5A1 gene technology reduces the amounts of two core proteins in HIV cells by approximately 50%, suggesting that the technology suppresses replication of the virus.
Subscribe to our email newsletter
The levels of the proteins, p24, a core protein in HIV cells, and IL-8, a pro-inflammatory cytokine, rise proportionately with increased HIV replication, making both of them standard indicators of HIV-1 infection.
Using a chronically HIV-1 infected human cell line, researchers at the University of Colorado performed the studies for the company.
The HIV cell line was transfected with a small interfering RNA to eIF-5A1 and then levels of p24 or IL-8 were measured 72 hours later. Reduced levels of p24 and IL-8 correlate to suppressed replication of HIV-1.
“Although these results represent early stages of investigation, they are promising for two reasons. First, these proof-of-concept studies suggest that eIF-5A1 is a viable target for HIV drug discovery. Second, eIF-5A1 is a molecule made by the cell and not the virus. Therefore, the eIF-5A1 target does not mutate and an anti-HIV strategy using this target may not be hampered by resistance brought about by viral mutation,” said Dr Leland Shapiro, lead investigator at the University of Colorado.